|
The COVID-19 pandemic could hasten the switch to tenecteplase (TNKase) from other thrombolytic therapies for stroke treatment, thanks to its workflow advantages and the need to conserve alteplase (Activase) because of its growing use in COVID-19 patients, some specialists argued.
|